Lenvatinib inhibits the TGF-β1/Smad3 pathway by activating AZGP1 expression and reversing the EMT progression of ICC caused by AZGP1 deletion. This evidence concerns the gene AZGP1 and intrahepatic cholangiocarcinoma.